2. Signaling Pathways
  3. Neuronal Signaling
  4. Monoamine Oxidase
  5. MAO-A Isoform

MAO-A

Monoamine Oxidase A

 

MAO-A Related Products (117):

Cat. No. Product Name Effect Purity
  • HY-108048
    Desoxypeganine
    		Inhibitor
    Desoxypeganine (Deoxypeganine), an alkaloid, is a potent and orally active cholinesterase (BChE and AChE) and selective MAO-A inhibitor, with IC50 values of 2, 17, and 2 μM, respectively. Desoxypeganine can be used for alcohol abuse research.
  • HY-181041
    Multitarget AD-IN-5
    		Inhibitor
    Multitarget AD-IN-5 (Compound 20), 9-Aminoacridine (HY-B1422) derivative, is a neuroprotective agent. Multitarget AD-IN-5 shows IC50 values of 0.614, 0.448, 3.73 and 1.55 μM for hAChE, hBChE, hMAO-A and hMAO-B. Multitarget AD-IN-5 can reduce length and diameter of Aβ42 fibers, and decrease the number of fibers per unit area. Multitarget AD-IN-5 can be used for research of Alzheimer's disease.
  • HY-115986
    MAO-B-IN-5
    		Inhibitor
    MAO-B-IN-5 is a potent, selective and orally active MAO-B inhibitor with an IC50 of 0.204 µM. MAO-B-IN-5 has the potential for the research of Parkinson's disease (PD).
  • HY-180783
    AChE/BChE/MAO-A-IN-1
    		Inhibitor
    AChE/BChE/MAO-A-IN-1 (Compound 5c) is a multi-target inhibitor with IC₅₀ values for AChE, BChE, and MAO-A of 78.7, 22.63, and 0.84 μM respectively. AChE/BChE/MAO-A-IN-1 can be used for the research of Alzheimer's disease.
  • HY-178149
    MAO-A/B-IN-5
    		Inhibitor
    MAO-A/B-IN-5 is an orally active MAO-A (IC50 = 73.88 μM) and MAO-B (IC50 = 91.08 μM) inhibitor. MAO-A/B-IN-5 reverses Sodium nitroprusside (SNP) (HY-B0564)-induced cerebral lipid peroxidation (IC50 = 130.2 μM) and protein carbonylation (IC50 = 229.8 μM). MAO-A/B-IN-5 shows dose-dependent and time-dependent antidepressant-like efficacy in mice. MAO-A/B-IN-5 can be used for the study of depressive disorder.
  • HY-149978
    LSD1-IN-26
    		Inhibitor
    LSD1-IN-26 (compound 12u) is a potent LSD1 inhibitor, with an IC50 of 25.3 nM. LSD1-IN-26 also inhibits MAO-A (IC50=1234.57 nM) and MAO-B (IC50=3819.27 nM). LSD1-IN-26 significantly induces apoptosis in MGC-803 cells. LSD1-IN-26 can be used for gastric cancer research.
  • HY-143438
    2-PAT
    		Inhibitor
    2-PAT, an analogue of Rasagiline and Selegiline, a reversible MAO-A inhibitor with an IC50 of 0.721 µM. 2-PAT is an inactivator of MAO-B with an IC50 of 14.6 µM. 2-PAT has the potential for Parkinson’s disease and depression research.
  • HY-101392R
    Harmane (Standard)
    		Inhibitor
    Harmane (Standard) is the analytical standard of Harmane. This product is intended for research and analytical applications. Harmane, a β-Carboline alkaloid (BCA), is a potent neurotoxin that causes severe action tremors and psychiatric manifestations. Harmane shows 1000-fold selectivity for I1-Imidazoline receptor (IC50=30 nM) over α2-adrenoceptor (IC50=18 μM). Harmane is also a potent and selective inhibitor of monoamine oxidase (MAO) (IC50s=0.5 and 5 μM for human MAO A/B, respectively). Harmane exhibits comutagenic effect.
  • HY-W207699
    MAO-B-IN-46
    		Inhibitor
    MAO-B-IN-46 (Compound 16) is a selective hMAO-B inhibitor (IC50: 26.8 nM), with weak activity against hMAO-A (IC50: 7.2054 μM). MAO-B-IN-46 (Compound 8) also acts as an α-amylase inhibitor (IC50: 19.46 μM). MAO-B-IN-46 exhibits certain neuroprotective effects and shows no significant toxicity to human gingival fibroblasts and SH-SY5Y cells. Additionally, MAO-B-IN-46 can scavenge DPPH and ABTS free radicals, with IC50 values of 17.86 μM and 17.71 μM, respectively. MAO-B-IN-46 can be used in the research of neurodegenerative diseases such as Parkinson's disease, diabetes, and diseases related to oxidative stress resistance.
  • HY-178352
    MAO-B-IN-49
    		Inhibitor
    MAO-B-IN-49 is a selective and reversible MAO-B inhibitor (IC50 of 1 nM for human MAO-B). MAO-B-IN-49 shows much higher selectivity for MAO-B than for MAO-A (IC50 = 633.9 μM). MAO-B-IN-49 can reduce ROS production induced by Lipopolysaccharides (HY-D1056) (LPS) in HT22 cells. MAO-B-IN-49 demonstrates substantial neuroprotective properties and significantly improves motor dysfunction in MPTP (HY-W114750)-induced mouse models of Parkinson’s disease (PD). MAO-B-IN-49 can be used for the study of PD.
  • HY-N18471
    5,7-Dihydroxytryptamine
    		Ligand
    5,7-Dihydroxytryptamine (5,7-DHP) is an autofluorescent (λex≈365 nm), selective neurotoxin and a transport substrate for MAO-A and 5-HT. 5,7-Dihydroxytryptamine can specifically target and damage central and peripheral 5-HTergic neurons, while affecting 5-HT-related pathways and neurotransmitter balance. 5,7-Dihydroxytryptamine can be used to establish 5-HTergic neuron injury models for studies on neural development, neurodegenerative diseases, as well as mechanisms related to platelet function and retinal neurons.
  • HY-173288
    MAO-B-IN-40
    		Inhibitor
    MAO-B-IN-40 (3a), a MAOB inhibitor (IC50 = 0.493 μM for hMAOB), demonstrates robust neuroprotective and antioxidant effect. MAO-B-IN-40 (3a) can be used in the research of Parkinson’s disease.
  • HY-100679B
    (R)-Pirlindole mesylate
    		Inhibitor
    (R)-Pirlindole mesylate is selective and reversible a Monoamine oxidase A (MAO-A) inhibitor with an IC50 of 0.43  μM for MAO-A over MAO-B. (R)-Pirlindole mesylate has an antidepressant activity. (R)-Pirlindole mesylate significantly decreases immobility time of the forced swim test and inhibits Reserpine (HY-N0480)-induced palpebral ptosis in behavioural mice models. (R)-Pirlindole mesylate can be used for depression research.
  • HY-158334
    NDs-IN-1
    		Inhibitor
    (Neurodegenerative diseases) NDs-IN-1 (Compound 3g) inhibits the activities of key enzymes such as hBACE-1, hAChE and hMAO-B. NDs-IN-1 is a novel non-covalent multi-target inhibitor. NDs-IN-1 is mainly used in the study of neurodegenerative diseases.
  • HY-149242
    MAO-B-IN-20
    		Inhibitor
    MAO-B-IN-20 (Compound C14) is a potent MAO-B inhibitor with an IC50 of 0.037 μM. MAO-B-IN-20 displays good metabolic stability and brain-blood barrier permeability. MAO-B-IN-20 can be used for the research of Parkinson's disease.
  • HY-170487
    MAO-B-IN-38
    		Inhibitor
    MAO-B-IN-38 (Compound 6b) is a reversible and competitive MAO-B inhibitor, with IC50 values of 0.03 and 21.46 µM for MAO-B and MAO-A, respectively. MAO-B-IN-38 can be used for the research of neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases.
  • HY-178454
    Multitarget AD-IN-3
    		Inhibitor
    Multitarget AD-IN-3 is a brain-penetrant neuroprotective agent. Multitarget AD-IN-3 can selectively inhibit MAO-B with an IC50 of 4.42 μM and a SI of 18.12. Multitarget AD-IN-3 can eliminate ROS. Multitarget AD-IN-3 Multitarget AD-IN-3 can inhibit Aβ1-42 self-aggregation and can reverse Aβ1-42-induced mitochondrial membrane depolarization and inhibit apoptosis. Multitarget AD-IN-3 can be used for the research of neurological disease, such as Alzheimer’s disease.
  • HY-N1636
    1-Methyl-2-nonyl-4(1H)-quinolone
    		Inhibitor
    1-Methyl-2-nonyl-4(1H)-quinolone, a quinolone alkaloid, is a potent and selective MAO-B (monoamine oxidase) inhibitor. 1-Methyl-2-nonyl-4(1H)-quinolone exhibites inhibitory activity on leukotriene biosynthesis, with an IC50 of 12.1 μM.
  • HY-180842
    MAO-B-IN-50
    		Inhibitor
    MAO-B-IN-50 (Compound C20) is a selective MAO-B inhibitor with an IC50 value of 0.06 μM. MAO-B-IN-50 shows good inhibitory effects on the aggregation of Aβ40/42 and Tau proteins, with overall IC50 values around 1 μM. MAO-B-IN-50 exhibits potent and selective AChE inhibition (IC50 = 1.78 μM). MAO-B-IN-50 can be used in the research of Alzheimer's disease.
  • HY-151210
    MAO-B-IN-17
    		Inhibitor ≥99.0%
    MAO-B-IN-17 is a selective monoamine oxidase B (MAO-B) inhibitor with the IC50 value of 5.08 μM. MAO-B-IN-17 can be used in Parkinson’s disease research.